The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality

被引:4
作者
Lobaina, Yadira [1 ,2 ]
Chen, Rong [1 ,3 ]
Suzarte, Edith [4 ]
Ai, Panchao [1 ,3 ]
Huerta, Vivian [1 ,4 ]
Musacchio, Alexis [1 ,4 ]
Silva, Ricardo [1 ,5 ]
Tan, Changyuan [1 ,3 ]
Martin, Alejandro [4 ]
Lazo, Laura [4 ]
Guillen-Nieto, Gerardo [4 ]
Yang, Ke [1 ,3 ]
Perera, Yasser [1 ,2 ,4 ]
Hermida, Lisset [1 ,3 ,5 ]
机构
[1] China Cuba Biotechnol Joint Innovat Ctr CCBJ, Res Dept, Yongzhou 425000, Peoples R China
[2] Yongzhou Zhong Gu Biotechnol Co Ltd, R&D Dept, Yangjiaqiao St, Yongzhou 425000, Peoples R China
[3] Yongzhou Dev & Construct Investment Co Ltd YDCI, Changfeng Ind Pk,1 Liebao Rd, Yongzhou 425000, Peoples R China
[4] Ctr Genet Engn & Biotechnol, CIGB Res Dept, Havana 10600, Cuba
[5] Representat Off BCF China, BCF R&D Sect, Jingtai Tower,24 Jianguomen Wai St, Beijing 100022, Peoples R China
来源
VIRUSES-BASEL | 2024年 / 16卷 / 03期
基金
国家重点研发计划;
关键词
SARS-CoV-2; broad vaccine; intranasal; ODN; cell-mediated immunity; neutralizing Abs; bivalent vaccine; IMMUNE-RESPONSE; MICE; INFECTION; MUCOSAL; IMPACT; CELLS; DNA;
D O I
10.3390/v16030418
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Despite the rapid development of vaccines against COVID-19, they have important limitations, such as safety issues, the scope of their efficacy, and the induction of mucosal immunity. The present study proposes a potential component for a new generation of vaccines. The recombinant nucleocapsid (N) protein from the SARS-CoV-2 Delta variant was combined with the ODN-39M, a synthetic 39 mer unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), used as an adjuvant. The evaluation of its immunogenicity in Balb/C mice revealed that only administration by intranasal route induced a systemic cross-reactive, cell-mediated immunity (CMI). In turn, this combination was able to induce anti-N IgA in the lungs, which, along with the specific IgG in sera and CMI in the spleen, was cross-reactive against the nucleocapsid protein of SARS-CoV-1. Furthermore, the nasal administration of the N + ODN-39M preparation, combined with RBD Delta protein, enhanced the local and systemic immune response against RBD, with a neutralizing capacity. Results make the N + ODN-39M preparation a suitable component for a future intranasal vaccine with broader functionality against Sarbecoviruses.
引用
收藏
页数:22
相关论文
共 71 条
  • [1] Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
    Afkhami, Sam
    D'Agostino, Michael R.
    Zhang, Ali
    Stacey, Hannah D.
    Marzok, Art
    Kang, Alisha
    Singh, Ramandeep
    Bavananthasivam, Jegarubee
    Ye, Gluke
    Luo, Xiangqian
    Wang, Fuan
    Ang, Jann C.
    Zganiacz, Anna
    Sankar, Uma
    Kazhdan, Natallia
    Koenig, Joshua F. E.
    Phelps, Allyssa
    Gameiro, Steven F.
    Tang, Shangguo
    Jordana, Manel
    Wan, Yonghong
    Mossman, Karen L.
    Jeyanathan, Mangalakumari
    Gillgrass, Amy
    Medina, Maria Fe C.
    Smaill, Fiona
    Lichty, Brian D.
    Miller, Matthew S.
    Xing, Zhou
    [J]. CELL, 2022, 185 (05) : 896 - +
  • [2] Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B
    Aguilar, Julio Cesar
    Aguiar, Jorge Agustin
    Akbar, Sheikh Mohammad Fazle
    [J]. VACCINES, 2022, 10 (12)
  • [3] The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
    Ahlen, Gustaf
    Frelin, Lars
    Nikouyan, Negin
    Weber, Friedemann
    Hoglund, Urban
    Larsson, Olivia
    Westman, Marie
    Tuvesson, Ola
    Gidlund, Eva-karin
    Cadossi, Matteo
    Appelberg, Sofia
    Mirazimi, Ali
    Sallberg, Matti
    [J]. JOURNAL OF VIROLOGY, 2020, 94 (18)
  • [4] Ahn J.Y., 2021, medRxiv, DOI [10.1101/2021.05.26.21257700, DOI 10.1101/2021.05.26.21257700]
  • [5] Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
    Al Kaabi, Nawal
    Zhang, Yuntao
    Xia, Shengli
    Yang, Yunkai
    Al Qahtani, Manaf M.
    Abdulrazzaq, Najiba
    Al Nusair, Majed
    Hassany, Mohamed
    Jawad, Jaleela S.
    Abdalla, Jehad
    Hussein, Salah Eldin
    Al Mazrouei, Shamma K.
    Al Karam, Maysoon
    Li, Xinguo
    Yang, Xuqin
    Wang, Wei
    Lai, Bonan
    Chen, Wei
    Huang, Shihe
    Wang, Qian
    Yang, Tian
    Liu, Yang
    Ma, Rui
    Hussain, Zaidoon M.
    Khan, Tehmina
    Saifuddin Fasihuddin, Mohammed
    You, Wangyang
    Xie, Zhiqiang
    Zhao, Yuxiu
    Jiang, Zhiwei
    Zhao, Guoqing
    Zhang, Yanbo
    Mahmoud, Sally
    ElTantawy, Islam
    Xiao, Peng
    Koshy, Ashish
    Zaher, Walid Abbas
    Wang, Hui
    Duan, Kai
    Pan, An
    Yang, Xiaoming
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 35 - 45
  • [6] A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
    An, Yaling
    Li, Shihua
    Jin, Xiyue
    Han, Jian-Bao
    Xu, Kun
    Xu, Senyu
    Han, Yuxuan
    Liu, Chuanyu
    Zheng, Tianyi
    Liu, Mei
    Yang, Mi
    Song, Tian-Zhang
    Huang, Baoying
    Zhao, Li
    Wang, Wen
    A, Ruhan
    Cheng, Yingjie
    Wu, Changwei
    Huang, Enqi
    Yang, Shilong
    Wong, Gary
    Bi, Yuhai
    Ke, Changwen
    Tan, Wenjie
    Yan, Jinghua
    Zheng, Yong-Tang
    Dai, Lianpan
    Gao, George F.
    [J]. EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 1058 - 1071
  • [7] Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
  • [8] Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
    Bernal, Jamie Lopez
    Andrews, Nick
    Gower, Charlotte
    Gallagher, Eileen
    Simmons, Ruth
    Thelwall, Simon
    Stowe, Julia
    Tessier, Elise
    Groves, Natalie
    Dabrera, Gavin
    Myers, Richard
    Campbell, Colin N. J.
    Amirthalingam, Gayatri
    Edmunds, Matt
    Zambon, Maria
    Brown, Kevin E.
    Hopkins, Susan
    Chand, Meera
    Ramsay, Mary
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) : 585 - 594
  • [9] Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
  • [10] Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2
    Cao, Huibi
    Mai, Juntao
    Zhou, Zhichang
    Li, Zhijie
    Duan, Rongqi
    Watt, Jacqueline
    Chen, Ziyan
    Bandara, Ranmal Avinash
    Li, Ming
    Ahn, Sang Kyun
    Poon, Betty
    Christie-Holmes, Natasha
    Gray-Owen, Scott D.
    Banerjee, Arinjay
    Mossman, Karen
    Kozak, Rob
    Mubareka, Samira
    Rini, James M.
    Hu, Jim
    Liu, Jun
    [J]. CELL AND BIOSCIENCE, 2021, 11 (01)